RTP Mobile Logo
The Implications of New Research Findings for the Management of Endometrial Cancer (Webinar Audio Proceedings)
Released July 2023

Featuring perspectives from Dr Bradley J Monk and Dr Matthew A Powell. Published July 14, 2023. (Webinar Audio Proceedings)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity is intended for gynecologic oncologists, medical and radiation oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of endometrial cancer.

    LEARNING OBJECTIVES

    • Evaluate the importance of microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiency assessment for patients with endometrial cancer, and adapt current testing practices to optimally identify genetic abnormalities.
    • Review the benefits observed with anti-PD-1/PD-L1 antibodies for MSI-high or MMR-deficient endometrial cancer, and appropriately integrate these agents into the care of patients.
    • Recognize the biologic rationale for and available data with the combination of anti-PD-1/PD-L1 antibodies with agents targeting the VEGF pathway, and select patients with metastatic endometrial cancer for this novel approach.
    • Design and implement a plan of care to manage side effects and toxicities associated with immune checkpoint inhibitor-based therapies for endometrial cancer in order to support quality of life and continuation of treatment.
    • Describe the scientific justification for, published research data with and toxicity profiles of novel agents and strategies under investigation for endometrial cancer, and effectively prioritize clinical trial opportunities for eligible patients.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    PRIVACY POLICY
    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Bradley J Monk, MD
    Professor
    Division of Gynecologic Oncology
    University of Arizona College of Medicine
    Creighton University School of Medicine
    Phoenix, Arizona

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, ImmunoGen Inc, Karyopharm Therapeutics, Merck, Myriad Genetic Laboratories Inc, Novocure Inc, Seagen Inc, Tesaro, A GSK Company; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, ImmunoGen Inc, Merck, Myriad Genetic Laboratories Inc, Tesaro, A GSK Company.

    Matthew A Powell, MD
    Professor, Department of Obstetrics and Gynecology
    Washington University School of Medicine
    St Louis, Missouri

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GSK, Merck, Roche Laboratories Inc, Seagen Inc; Contracted Research: GSK.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from GSK and Merck.

    Release date: July 2023
    Expiration date: July 2024

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):